These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27482595)

  • 1. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
    Liu S; Dozois MD; Chang CN; Ahmad A; Ng DL; Hileeto D; Liang H; Reyad MM; Boyd S; Jones LW; Gu FX
    Mol Pharm; 2016 Sep; 13(9):2897-905. PubMed ID: 27482595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.
    Tan G; Li J; Song Y; Yu Y; Liu D; Pan W
    Acta Biomater; 2019 Nov; 99():350-362. PubMed ID: 31449929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery.
    Prosperi-Porta G; Kedzior S; Muirhead B; Sheardown H
    Biomacromolecules; 2016 Apr; 17(4):1449-57. PubMed ID: 26963738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine Amicellar delivery system for dry eyes.
    Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
    Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels.
    Lin PH; Jian HJ; Li YJ; Huang YF; Anand A; Huang CC; Lin HJ; Lai JY
    Acta Biomater; 2022 Mar; 141():140-150. PubMed ID: 35081433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
    Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
    Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of hyaluronic acid to the ocular surface by a polymer-peptide conjugate system for dry eye disease.
    Lee D; Lu Q; Sommerfeld SD; Chan A; Menon NG; Schmidt TA; Elisseeff JH; Singh A
    Acta Biomater; 2017 Jun; 55():163-171. PubMed ID: 28363785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
    Bang SP; Yeon CY; Adhikari N; Neupane S; Kim H; Lee DC; Son MJ; Lee HG; Kim JY; Jun JH
    PLoS One; 2019; 14(11):e0224805. PubMed ID: 31738791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion.
    Karn PR; Kim HD; Kang H; Sun BK; Jin SE; Hwang SJ
    Int J Nanomedicine; 2014; 9():3791-800. PubMed ID: 25143728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review: topical ophthalmic use of cyclosporin A.
    Utine CA; Stern M; Akpek EK
    Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
    Gehlsen U; Braun T; Notara M; Krösser S; Steven P
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief.
    Huang HY; Wang MC; Chen ZY; Chiu WY; Chen KH; Lin IC; Yang WV; Wu CC; Tseng CL
    Int J Nanomedicine; 2018; 13():7251-7273. PubMed ID: 30510416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
    Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
    Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
    Dutescu RM; Panfil C; Merkel OM; Schrage N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
    Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
    J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
    Kovalchin J; King B; Masci A; Hopkins E; Fry J; Hou J; Li C; Tenneson K; Weber S; Wolfe G; Collins K; Furfine ES
    Eye Contact Lens; 2018 May; 44(3):170-181. PubMed ID: 28727604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
    Mandal A; Gote V; Pal D; Ogundele A; Mitra AK
    Pharm Res; 2019 Jan; 36(2):36. PubMed ID: 30617777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
    Liu Y; Wang Y; Yang J; Zhang H; Gan L
    Int J Pharm; 2019 Jun; 565():133-142. PubMed ID: 31075435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.